These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33504634)

  • 21. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context.
    Sormani MP; Schiavetti I; Carmisciano L; Cordioli C; Filippi M; Radaelli M; Immovilli P; Capobianco M; De Rossi N; Brichetto G; Cocco E; Scandellari C; Cavalla P; Pesci I; Zito A; Confalonieri P; Marfia GA; Perini P; Inglese M; Trojano M; Brescia Morra V; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of COVID-19 in patients with rheumatic disease: is prior health education more important than shielding advice during the pandemic?
    Kipps S; Paul A; Vasireddy S
    Clin Rheumatol; 2021 Apr; 40(4):1575-1579. PubMed ID: 33174109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors Associated with a Positive Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Suspected Cases Presenting with Pneumonia: A Retrospective Cohort Study in a Single Medical Center.
    Li Y; Shang Y; Yang Y; Wang M; Yu D; Su D; Liu L; Wang Q; Zhang X; Ren J; Chen H
    Respiration; 2020; 99(9):739-747. PubMed ID: 33207356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC).
    Klineova S; Harel A; Straus Farber R; DeAngelis T; Zhang Y; Hentz R; Leung TM; Fong K; Smith T; Blanck R; Zhovtis-Ryerson L
    Mult Scler Relat Disord; 2021 Oct; 55():103153. PubMed ID: 34392059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis.
    Sahraian MA; Azimi A; Navardi S; Ala S; Naser Moghadasi A
    Mult Scler Relat Disord; 2020 Nov; 46():102472. PubMed ID: 32890817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Headache as a Cardinal Symptom of Coronavirus Disease 2019: A Cross-Sectional Study.
    Membrilla JA; de Lorenzo Í; Sastre M; Díaz de Terán J
    Headache; 2020 Nov; 60(10):2176-2191. PubMed ID: 32989732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiological study of multiple sclerosis in La Rioja.
    Bártulos Iglesias M; Marzo Sola ME; Estrella Ruiz LA; Bravo Anguiano Y
    Neurologia; 2015; 30(9):552-60. PubMed ID: 24975346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple sclerosis is associated with worse COVID-19 outcomes compared to the general population: A population-based study.
    Barzegar M; Sindarreh S; Manteghinejad A; Mirmosayyeb O; Mazaheri S; Rahimi M; Javanmard SH; Shaygannejad V; Nasirian M
    Mult Scler Relat Disord; 2023 Nov; 79():104947. PubMed ID: 37659351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea.
    You JH; Lee SA; Chun SY; Song SO; Lee BW; Kim DJ; Boyko EJ
    Endocrinol Metab (Seoul); 2020 Dec; 35(4):901-908. PubMed ID: 33297603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of multiple sclerosis in Santiago de Compostela (Spain).
    Costa Arpín E; Naveiro Soneira J; Lema Bouzas M; González Quintela A; Prieto González JM
    Acta Neurol Scand; 2020 Sep; 142(3):267-274. PubMed ID: 32392359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study.
    Zhang Y; Staker E; Cutter G; Krieger S; Miller AE
    Mult Scler Relat Disord; 2021 May; 50():102856. PubMed ID: 33662858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain.
    Vila-Córcoles A; Ochoa-Gondar O; Satué-Gracia EM; Torrente-Fraga C; Gomez-Bertomeu F; Vila-Rovira A; Hospital-Guardiola I; de Diego-Cabanes C; Bejarano-Romero F; Basora-Gallisà J
    BMJ Open; 2020 Dec; 10(12):e041577. PubMed ID: 33303459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients in a MERS-CoV Endemic Area.
    Barry M; AlMohaya A; AlHijji A; Akkielah L; AlRajhi A; Almajid F; Alsharidi A; Al-Shahrani FS; Alotaibi NH; Alanazi A; Ghonem L; Alhetheel A; Alsubaie S; Memish ZA
    J Epidemiol Glob Health; 2020 Sep; 10(3):214-221. PubMed ID: 32954712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk and outcomes of COVID-19 in patients with multiple sclerosis.
    Moreno-Torres I; Meca Lallana V; Costa-Frossard L; Oreja-Guevara C; Aguirre C; Alba Suárez EM; Gómez Moreno M; Borrega Canelo L; Sabín Muñoz J; Aladro Y; Cárcamo A; Rodríguez García E; Cuello JP; Monreal E; Sainz de la Maza S; Pérez Parra F; Valenzuela Rojas F; López de Silanes de Miguel C; Casanova I; Martínez Gines ML; Blasco R; Orviz García A; Villar-Guimerans LM; Fernández-Dono G; Elvira V; Santiuste C; Espiño M; García Domínguez JM
    Eur J Neurol; 2021 Nov; 28(11):3712-3721. PubMed ID: 34152073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey.
    Ricardo A; Carnero Contentti E; Anabel SB; Adrian LP; Orlando G; Fernando H; Víctor R; Fernando G; Ignacio RJ
    Mult Scler Relat Disord; 2020 Sep; 44():102310. PubMed ID: 32590314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension.
    Mancusi C; Grassi G; Borghi C; Carugo S; Fallo F; Ferri C; Giannattasio C; Grassi D; Letizia C; Minuz P; Muiesan ML; Perlini S; Pucci G; Rizzoni D; Salvetti M; Sarzani R; Sechi L; Veglio F; Volpe M; Iaccarino G;
    J Hypertens; 2021 Feb; 39(2):376-380. PubMed ID: 33186327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 infections in the Friuli Venezia Giulia Region (Northern Italy): a population-based retrospective analysis.
    Calagnan E; Gobbato M; Burba I; Del Zotto S; Toffolutti F; Serraino D; Tonutti G
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):323-329. PubMed ID: 33412825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
    Gaindh D; Kavak KS; Teter B; Vaughn CB; Cookfair D; Hahn T; Weinstock-Guttman B;
    J Neurol Sci; 2016 Nov; 370():13-17. PubMed ID: 27772741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study.
    Al-Sakran L; Marrie RA; Blackburn D; Knox K; Evans C
    BMJ Open; 2019 Nov; 9(11):e033599. PubMed ID: 31772108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of somatic comorbidities among coronavirus disease 2019 patients in Croatia in the first pandemic wave: data from national public health databases.
    Capak K; Brkić-Biloš I; Kralj V; Poljičanin T; Šekerija M; Ivanko P; Draušnik Ž; Mihel S; Fuštin D; Cerovečki I; Švajda M; Dimnjaković J; Sarajlić G; Benjak T
    Croat Med J; 2020 Dec; 61(6):518-524. PubMed ID: 33410298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.